TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 195190
Drug: CL 88,277
Approvals — FDA: no, EMA: no, PMDA: no
Description: CL 88,277 (250 mg, 1 ml administered three times a day plus one dose prior to challenge and for six consecutive post-challenge days)
Study: 29749716
Drug: Test dalfampridine
Normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test dalfampridine tablet (generic formulation)
Study: 29749716
Drug: Branded dalfampridine
Normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded dalfampridine tablet (reference formulation)
Study: 28829368
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of grape and apple polyphenols
Study: 23780354
Drug: PC: positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC: positive control group (no medication)
Study: 14975461
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of half-dose reteplase and abciximab
Study: 11725230
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (lumbar fusion)
Study: 11725230
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment (physical therapy)
Study: 8204228
Drug: Chronic calcium
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic calcium channel blockers
Study: 8204228
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium channel blockers
Study: 3144169
Drug: Oral encainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral encainide (75 to 200 mg/day)
Study: 3144169
Drug: Oral quinidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinidine (1,200 mg/day)
Study: 28187222
Drug: 50 µg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg/wk 25‐hydroxyvitamin‐D3
Study: 28187222
Drug: 150 µg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 µg/wk vitamin D3
Study: 28187222
Drug: Control cells
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cells (not specified dosage)
Study: 23881439
Drug: Alendronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (35 mg/week) and calcium lactate (600 mg/day)
Study: 23881439
Drug: Calcium lactate
Normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactate (600 mg/day)
Study: 19808656
Drug: Intravenous fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous fructose (0.5 g/kg)
Study: 19808656
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (0.5 g/kg)
Study: 15799911
Drug: Amiodarone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone therapy for 3 months post-surgery
Study: 11055218
Drug: Vitrectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitrectomy with intravitreal administration of 0.4 mg gentamicin
Study: 23377509
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1.2% and tretinoin 0.025% gel (ZIANA)
Study: 12814846
Drug: Coping-oriented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping-oriented therapy approach
Study: 10227413
Drug: Regular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular administration of antihypertensive medication
Study: 1909218
Drug: rt‐PA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA (100 mg over a 3‐hour period)
Study: 30593884
Drug: Patient-completed Decision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-completed Decision Support Tool (DST) for mental health care, including feedback on DST responses, treatment priorities, motivation assessment, and severity-matched treatment recommendations.
Study: 22492501
Drug: synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: synthetic human PTH 1‐34 (hPTH 1‐34), injected two to three times daily for 18 months
Study: 17202798
Drug: Propofol (induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (induction 1.5 mg/kg, maintenance 1.5 mg kg(‐1) h(‐1))
Study: 17202798
Drug: Midazolam (induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (induction 0.5 mg/kg, maintenance 0.1 mg kg(‐1) h(‐1))
Study: 10573224
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with dihaematoporphyrin ether and argon dye laser photoradiation
Study: 6753120
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg daily
Study: 28255849
Drug: Cladribine (CdA)
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine (CdA) as a single agent or in combination with interferon (IFN) β‐1a
Study: 16913434
Drug: 5‐HT at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT at 1,000 micromol/L
Study: 16913434
Drug: 5‐HT at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT at 0.1 micromol/L
Study: 11132390
Drug: Mycobacterium vaccae
Normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium vaccae (0.1 mL)
Study: 11132390
Drug: Placebo (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.1 mL tetanus toxoid)
Study: 9061219
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oral prednisolone/day for 2 weeks
Study: 9061219
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral prednisolone/day for 2 weeks
Study: 9061219
Drug: 3.2 mg
Normalized name: menthol 3.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 mg inhaled budesonide/day for 2 weeks
Study: 3535621
Drug: Phenylpropanolamine (Rinexin)
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine (Rinexin) 50 mg twice daily
Study: 30218844
Drug: 3-month dual
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitor
Study: 12665540
Drug: 80% theta(L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% theta(L)
Study: 11013280
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m(2), 3-hour infusion) and cisplatin (80 mg/m(2)) every 21 days
Study: 11013280
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (100 mg/m(2))
Study: 8780837
Drug: Naltrexone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (1 mg/kg daily for 4 weeks)
Study: 1622413
Drug: Methotrexate sodium
Normalized name: Methotrexate Sodium
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate sodium tablets (7.5 mg dose, three 2.5 mg tablets) administered after an overnight fast
Study: 1622413
Drug: Methotrexate sodium
Normalized name: Methotrexate Sodium
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate sodium tablets (7.5 mg dose, three 2.5 mg tablets) administered within 10 minutes of consuming a high fat‐content breakfast
Study: 6421561
Drug: New glibenclamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: New glibenclamide preparation (Euglucon 5, HB 419)
Study: 6421561
Drug: Conventional glibenclamide
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional glibenclamide preparation (Euglucon N, HB 420)
Study: 29760159
Drug: MTX+ (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX+ (methotrexate therapy with hydroxychloroquine added if no remission)
Study: 27896461
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block using 20 mL of 0.375% ropivacaine
Study: 27896461
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group using 20 mL of 0.9% normal saline infusion
Study: 24532502
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of dual antiplatelet therapy (DAPT) due to unexpected requests for non-cardiac surgery or invasive procedures
Study: 24532502
Drug: Overall outcomes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall outcomes related to DAPT discontinuation
Study: 23731986
Drug: Irish set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irish set dancing classes once per week plus a weekly home program for 6 months
Study: 15986752
Drug: Postoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotic therapy and late suture removal
Study: 7482373
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (implied control)
Study: 7125306
Drug: Fenoterol 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol 5.0 mg
Study: 7125306
Drug: Fenoterol 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol 7.5 mg
Study: 7125306
Drug: Ephedrine 24
Normalized name: ephedrine 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 24 mg
Study: 29246256
Drug: Oral glycine
Normalized name: glycine Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glycine (0.5 g/kg/day, dissolved in any liquid)
Study: 24825180
Drug: Long-term proton
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term proton pump inhibitor therapy (>1 year)
Study: 17538639
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel (TTG) 50 mg/day for 3 months
Study: 17538639
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel (TTG)
Study: 15779317
Drug: Adper Prompt‐L‐Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt‐L‐Pop (AP, 3M ESPE) on dentin
Study: 15779317
Drug: Adper Prompt‐L‐Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt‐L‐Pop (AP, 3M ESPE) on enamel
Study: 11782694
Drug: Naftidrofuryl (Praxilene),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (Praxilene), 200 mg three times daily for 6 months
Study: 9513821
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for gastro-oesophageal reflux
Study: 9513821
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for non-ulcer dyspepsia with Helicobacter pylori eradication
Study: 9513821
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for duodenal ulceration
Study: 9513821
Drug: Prokinetic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prokinetic agent for non-ulcer dyspepsia
Study: 8443719
Drug: Cysteine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteine (200 mg orally four times a day)
Study: 8443719
Drug: Methylmethionine sulfonium
Normalized name: Dimethyl sulfone
DrugBank: Dimethyl sulfone (DB14090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylmethionine sulfonium chloride (MMSC) (500 mg orally four times a day)
Study: 3821139
Drug: Calea zacatechichi
Normalized name: Iresine calea extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calea zacatechichi extracts (low doses)
Study: 30241722
Drug: Azithromycin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (5 mg/kg per day for 21 days)
Study: 30241722
Drug: Amoxicillin-clavulanate (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (22.5 mg/kg, twice daily for 21 days)
Study: 27048694
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid 1g 10 min bolus followed by 1g 8h infusion
Study: 24754183
Drug: Reinforcing kidney,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcing kidney, activating blood circulation and ovarian stimulation compound recipe (treatment group)
Study: 18373490
Drug: Lumiracoxib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 200 mg once daily (q.d.)
Study: 18373490
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily (b.i.d.)
Study: 18373490
Drug: Lumiracoxib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 200 mg with a 200 mg redose (p.r.n.) on day 1
Study: 7792793
Drug: Potassium canrenoate
Normalized name: Potassium canrenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium canrenoate (K‐Can) 50 mg/day for 4 weeks
Study: 7792793
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 25 mg for 4 weeks
Study: 7792793
Drug: Furosemide 25
Normalized name: furosemide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 25 mg for 4 weeks
Study: 7792793
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 2 weeks before each treatment
Study: 1673723
Drug: Astemizole (H1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (H1 receptor blocker)
Study: 31086126
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus administered via nasogastric tube on Day 1
Study: 31086126
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus administered via nasogastric tube on Day 3
Study: 27858183
Drug: THP (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: THP (25 mg/m2 × 11)
Study: 27858183
Drug: DNR (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNR (30 mg/m2 × 11)
Study: 26109819
Drug: Recombinant streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant streptokinase (rSK) suppositories (200000 IU every 8 hours for the first 3 units, then every 12 hours until 8 administrations completed)
Study: 26109819
Drug: Hydrocortisone acetate
Normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone acetate suppositories (25 mg every 8 hours up to a maximum of 24 administrations)
Study: 26109819
Drug: Recombinant streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant streptokinase (rSK) suppositories (both schedules)
Study: 26109819
Drug: Hydrocortisone acetate
Normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone acetate suppositories
Study: 26109819
Drug: Recombinant streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant streptokinase (rSK) suppositories
Study: 22987606
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IPD and AD
Study: 17535995
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment, 0.33 mg/kg body weight per week for a mean of 6.7 years
Study: 15470332
Drug: SJW extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJW extract with high HYF content (900 mg/d)
Study: 15470332
Drug: SJW extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJW extract with low HYF content (900 mg/d)
Study: 7508396
Drug: 960 mg
Normalized name: glycerin 960 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960 mg cotrimoxazole and 10 mg oxazepam (group B)
Study: 7508396
Drug: 960 mg
Normalized name: glycerin 960 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960 mg cotrimoxazole (group A)
Study: 2730051
Drug: Juzentaiho-to (JTT)
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juzentaiho-to (JTT) combined with chemoendocrine therapy
Study: 2730051
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy only
Study: 807995
Drug: Flexical diet
Normalized name: Flexira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexical diet (semi‐hydrolyzed diet: 10 g % casein hydrolsate; 14 g % triglycerides, 20% of which medium chain; 66% disaccharides)
Study: 31161580
Drug: +O-desmethyltramadol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: +O-desmethyltramadol (200 mg extended-release tablets)
Study: 29250545
Drug: Simvastatin (preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (preoperative and postoperative administration)
Study: 25450879
Drug: Cisplatin 25
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m² and etoposide 100 mg/m² intravenously on days 1 to 3 (control arm)
Study: 25450879
Drug: Cisplatin 25
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m² and etoposide 100 mg/m² combined with bevacizumab 7.5 mg/kg intravenously on day 1 (experimental arm)
Study: 19761721
Drug: Subcutaneous epoietin-beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Subcutaneous epoietin-beta (0.3 ml = 4000 IU)
Study: 19761721
Drug: Subcutaneous darbepoietin-alpha
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous darbepoietin-alpha (0.5 ml = 20 microg)
Study: 19761721
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo (0.3 ml)
Study: 19761721
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo (0.5 ml)
Study: 19761721
Drug: Subcutaneous epoietin-beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Subcutaneous epoietin-beta
Study: 19761721
Drug: Subcutaneous darbepoietin-alpha
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous darbepoietin-alpha
Study: 15293466
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of traditional Chinese medicine and western medicine with massage and functional exercise (trial group)
Study: 15293466
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine and western medicine without massage and functional exercise (control group)
Study: 11062863
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of zolpidem (ZLP)
Study: 11062863
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of zopiclone (ZPC)
Study: 8405631
Drug: 17 beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol transdermally 0.05 mg/day on days 1‐24 and medroxyprogesterone acetate 10 mg/day orally on days 15‐24 (sequential schedule)
Study: 8405631
Drug: 17 beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol transdermally 0.05 mg/day and medroxyprogesterone acetate 2.5 mg/day orally on days 1‐24 (continuous schedule)
Study: 8405631
Drug: 17 beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol 0.05 mg/day continuously (in patients who had total abdominal hysterectomy+bilateral salphingooopherectomy)
Study: 2945332
Drug: Diltiazem (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (1.0 mg administered intracoronarily, distal from the stenosis)
Study: 31247504
Drug: Opioid agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid agonist treatment (OAT)
Study: 30621471
Drug: Guluronic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guluronic acid (G2013) 500 mg orally twice a day for 12 weeks
Study: 25068947
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 10 mg/kg intravenously 5 min before skin incision
Study: 23297844
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D3 supplementation (600 mg elemental calcium and 125 IU vitamin D3) with energy-restricted diet (‐500 kcal/d)
Study: 19131454
Drug: Subsidised nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subsidised nicotine replacement therapy (NRT) plus multisession counselling from the quitline
Study: 14749454
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate (2 g orally per day)
Study: 11705818
Drug: Conivaptan 20
Normalized name: conivaptan 20 mg/100 mL-D5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan 20 mg
Study: 11705818
Drug: Conivaptan 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan 40 mg
Study: 11705818
Drug: Conivaptan 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan 10 mg
Study: 9237061
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium supplementation with 2 g calcium per day
Study: 9237061
Drug: Oral dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dietary supplementation with 3.8 g of ispaghula husk
Study: 2884081
Drug: Ketotifen 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 2.0 mg
Study: 18656765
Drug: Dexamethasone injection
Normalized name: dexamethasone Injection
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone injection
Study: 18656765
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (lidocaine)
Study: 9603138
Drug: Zileuton (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton (600 mg)
Study: 8310508
Drug: 33B3.1 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33B3.1 (10 mg/day)
Study: 8310508
Drug: ATG (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG (1 mg/kg/day)